GlassScriptPhysician profile
Kimberly Ann Edwards
NPI 1639444136
$706.73
in general payments reported to CMS, 2019-2025
15 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $54.08 · 2024: $409 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.74 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $187.00 | 2024-2025 | |
| Janssen Biotech, INC. | $130.70 | 2024-2025 | Tremfya |
| Abbvie INC. | $61.57 | 2024-2025 | |
| Lilly USA, LLC | $51.09 | 2025 | Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $41.60 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $37.06 | 2024-2025 | Libtayo, Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.54 | 2024 | Spevigo |
| Organogenesis INC. | $27.34 | 2025 | Affinity |
| Incyte Corporation | $24.56 | 2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $23.76 | 2025 | Ycanth |
| Almirall LLC | $20.95 | 2025 | Klisyri |
| Depuy Synthes Sales INC. | $20.92 | 2023 | Orthovisc, Monovisc |
| Genzyme Corporation | $17.48 | 2024 | |
| Pfizer INC. | $16.77 | 2023 | |
| Acadia Pharmaceuticals INC | $16.39 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.